HC Wainwright Reaffirms Buy Rating for Imunon (NASDAQ:IMNN)

Imunon (NASDAQ:IMNN)‘s stock had its “buy” rating reissued by HC Wainwright in a report released on Wednesday,Benzinga reports. They currently have a $14.00 price target on the stock.

Separately, D. Boral Capital restated a “buy” rating and set a $29.00 price objective on shares of Imunon in a research note on Monday.

Imunon Price Performance

Shares of IMNN stock opened at $1.14 on Wednesday. The firm has a market cap of $16.67 million, a P/E ratio of -0.60 and a beta of 1.96. The firm has a fifty day moving average of $0.91 and a two-hundred day moving average of $0.92. Imunon has a 1-year low of $0.64 and a 1-year high of $3.65.

Institutional Trading of Imunon

A hedge fund recently raised its stake in Imunon stock. Geode Capital Management LLC lifted its holdings in shares of Imunon, Inc. (NASDAQ:IMNN) by 10.8% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 139,505 shares of the company’s stock after buying an additional 13,570 shares during the period. Geode Capital Management LLC owned 0.96% of Imunon worth $133,000 at the end of the most recent reporting period. 4.47% of the stock is currently owned by institutional investors and hedge funds.

About Imunon

Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development.